SOSAFE
6.7.2022 09:02:14 CEST | Business Wire | Press release
SoSafe – a leading provider of cyber security awareness – has hired former Smartly.io exec and experienced SaaS operator Felix Fichtl as CFO.
Fichtl brings with him more than a decade’s experience in building and scaling finance organisations across the SaaS industry. From both his previous role as CFO at the global social media advertising automation giant, Smartly.io to his time spearheading finance operations for market leaders zoovu (formerly SMARTASSISTANT) and SAP Hybris (now SAP CX).
His appointment comes as SoSafe looks to build on its recent growth and bring its human-centric approach to cybersecurity to the assistance of even more companies on an international scale. SoSafe is currently the market leader in cybersecurity awareness in its home country of Germany, and is one of the leading providers across Europe.
In January 2022, the company closed a $73 million Series B financing round, led by Highland Europe, to help fuel expansion into new territories and establish the firm as the global market leader. Part of these plans involve further bolstering the strength, experience and expertise of the existing C-suite team, of which Fichtl will now play a pivotal role.
With its data-driven and human-centric platform, SoSafe takes a unique, behavioural science approach to cybersecurity. An approach pioneered by its founder and CEO, psychologist Hellemann. Founded on the idea that 85% of cyberattacks on companies and organisations can be traced back to a human factor, SoSafe embeds deep gamification elements into the workflows of employees to foster and scale effective corporate security cultures.
SaaS industry leader Felix Fichtl from Smartly.io strengthens SoSafe's leadership team
During his tenure at Smartly.io, Fichtl scaled the finance organization and played a key role in the sale of a majority stake of the company to Providence Equity in 2019. During his time at SAP Hybris, he managed the post-merger integration of the Hybris side before taking responsibility as Division CFO for SAP Hybris (now SAP CX).
"SoSafe has a crystal-clear value proposition that addresses a key concern for companies worldwide. The company is well on its way to becoming a global champion in the area of cyber security," says Fichtl. ”Smartly.io, while initially a European player, became a global market leader during my time there. We need more of these success stories and I feel SoSafe has the potential to see such similar success. I am impressed by the team and the investors behind SoSafe and look forward to working with them," he adds.
“SoSafe’s C-level is brimming with experienced industry leaders, broad-based and complementary competencies, clear lines of responsibility and transparent structures. With Felix, we have gained an outstanding executive who perfectly complements this team," says Hellemann. “His appointment not only demonstrates our growth and our commitment to our customers, but it showcases our ambitions and will help us cement SoSafe as a global leader in cybersecurity awareness,” says Niklas Hellemann, co-founder and CEO of SoSafe.
SoSafe is currently scaling internationally and has recently opened hubs in Amsterdam, London, and Paris to manage new markets.
_______________
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by psychologist and former BCG consultant Niklas Hellemann, Digitalization Expert and previous McKinsey consultant Lukas Schaefer, and seasoned software engineer Felix Schuerholz. Today, it serves more than 2000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team now consists of more than 350 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom